ASCO: Akeso’s ivonescimab bests PD-1 inhibitor in lung cancer chemo combos, slashing death risk by 34%

Akeso’s ivonescimab plus chemotherapy delivered a statistically significant 34% overall survival improvement versus Tevimbra-chemo in first-line advanced squamous NSCLC, with median OS of 27.9 months vs 23.7 months and a p-value of 0.0017. The result strengthens the drug’s profile after prior PFS success, but ASCO discussants flagged concerns about immature follow-up, safety interpretation, and limited global applicability. The readout is likely to be sector-relevant for oncology biotech and could support sentiment around Akeso and the broader PD-1xVEGF class.

Analysis

This is a real competitive threat to legacy PD-1 + chemo franchise economics, but the market should treat it more as a China-specific commercialization win than a global category reset. The second-order effect is that ivonescimab now looks like the first credible attempt to “own” the VEGF add-on in squamous NSCLC, potentially pulling share from PD-1 incumbents in China and forcing global players to justify why they do not need a bispecific platform. For MRK, the issue is not immediate revenue loss from a single China study; it is the narrative erosion that Keytruda’s class advantage is no longer defensible in every frontline lung segment.

The bigger strategic read-through is that oncology’s next battleground may shift from pure checkpoint superiority to multi-pathway combinations with tolerability advantages. If that thesis holds, ONC-like platform companies with bispecific or multi-specific engineering capability become more valuable than single-asset immuno-oncology names, because the data show that merely matching PD-1 activity is no longer enough. That said, the applicability gap is material: the trial’s population and bleeding-risk exclusions mean ex-China regulators and clinicians will likely demand a broader safety dataset before re-rating the asset as a global standard.

Catalyst timing matters. In the next 1-3 months, expect volatility around follow-up duration, subgroup robustness, and any additional safety signal; in 6-12 months, the key question is whether ex-China trials reproduce the effect in older, more heterogeneous patients. The tail risk for bulls is that the apparent OS win compresses once mature follow-up and broader eligibility dilute the advantage, especially if treatment sequencing blunts the survival gap. The tail risk for bears is that this becomes the template for a class of differentiated lung cancer regimens and forces a pipeline repricing across PD-1 combinations.

Key Decisions for Investors

• Reduce MRK exposure tactically over the next 2-6 weeks into strength in order to hedge a widening narrative discount in first-line lung cancer; use a bearish call spread if you want defined risk, targeting a 2-3 month horizon.
• Long ONC on a 6-12 month view if valuation still reflects platform scarcity rather than product-level execution; the trade works best as a basket against single-asset immuno-oncology peers that lack bispecific optionality.
• Pair trade: short MRK / long ONC on a 3-6 month horizon to isolate the market’s likely overreaction to China-only data versus the broader platform re-rating opportunity.
• Avoid chasing the headline in the next few sessions; wait for post-ASCO digestion and any commentary on older-patient safety before adding risk, because the most attractive entry may come on a pullback once the global-applicability debate reasserts itself.
• If available, use event-driven options around the next Harmoni readout or regulatory update: long-dated upside on ONC-type platform exposure and limited-risk downside on MRK, since the core debate is now about durability and portability rather than initial efficacy.